在行动中Ceftolozane/tazobactam:在七个国家处方模式,有效性和医疗保健利用
Emre Yucel1, Alex Soriano2, David L Paterson3
1Global Pharma, Value & Implementation Outcomes Research, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA.
Journal of global antimicrobial resistance
|February 28, 2026
概括
塞夫托洛赞/塔扎巴克坦 (C/T) 在格拉姆阴性感染中使用,在七个国家显示了64.8%的临床成功率. 这些真实世界的数据提供了对治疗模式和资源利用的见解,以优化抗菌药物治疗.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 全球健康 全球健康
背景情况:
- 格拉姆阴性细菌的抗微生物耐药性构成了全球健康的重大挑战.
- 塞夫托洛赞/塔扎巴克坦 (C/T) 已被批准用于特定感染,但实际数据有限.
研究的目的:
- 描述在多个国家的成年住院患者中C/T的实际使用情况.
- 分析与C/T治疗相关的社会人口统计和临床特征,治疗模式,临床结果和资源利用情况.
主要方法:
- 追溯观察性研究 (SPECTRA) 涉及7个国家的617名成年住院患者.
- 患者在2016年至2020年期间至少接受了C/T治疗48小时.
- 收集关于患者特征,感染类型,治疗,结果和医疗资源利用情况的数据.
主要成果:
- 伴随性疾病因国家而异 (55.9%至91.7%).
- 对多种药物耐药的Pseudomonas aeruginosa在72.7%的培养阳性病例中被发现.
- 临床成功率为64.8%,其中在ICU治疗的患者中有51.1%.
结论:
- 这项跨国研究为C/T处方模式和医疗保健资源利用提供了有价值的现实洞察力.
- 调查结果强调了现实世界的数据对于告知临床实践和优化抗菌药物治疗的重要性.
- 现实世界的数据对于在各种医疗保健环境中管理格拉姆阴性感染至关重要.
相关概念视频
01:28Antimicrobial Effectiveness
1.4K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
1.4K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
233
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
233
01:29Therapeutic Drug Monitoring: Affecting Factors
288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
660
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
660
01:27Combined Effects of Drugs: Synergism
7.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.1K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54